SCHEMBL14360705

SCHEMBL14360705

COc1ccc(-c2ccc(C)n2C)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.50
KDM4E B2RXH2 4/20 0.44
ALDH1A1 P00352 4/20 0.44
ALOX15 P16050 3/20 0.44
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA7 P43166 1/20 0.44
CA9 Q16790 1/20 0.44
CA14 Q9ULX7 1/20 0.44
ACHE P22303 1/20 0.43
LMNA P02545 3/20 0.42
BACE1 P56817 1/20 0.42
ESR2 Q92731 1/20 0.42
GAA P10253 3/20 0.41
HPGD P15428 2/20 0.41
THRB P10828 1/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
APP P05067 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2573157 0.74 ALDH1A1 (0.53) MAPTKDM4EALDH1A1ALOX15CA12
SCHEMBL3761395 0.73 LMNA (0.66) MAPTKDM4EALDH1A1ALOX15CA1
SCHEMBL6287258 0.72 PDE4B (0.50) MAPTKDM4EALDH1A1ALOX15LMNA
SCHEMBL6287907 0.72 PDE4B (0.50) MAPTKDM4EALDH1A1ALOX15LMNA
SCHEMBL6287320 0.72 PDE4B (0.50) MAPTKDM4EALDH1A1ALOX15LMNA
SCHEMBL6286533 0.72 PDE4B (0.50) MAPTKDM4EALDH1A1ALOX15LMNA
SCHEMBL6287779 0.72 PDE4B (0.50) MAPTKDM4EALDH1A1ALOX15LMNA
SCHEMBL6287191 0.72 PDE4B (0.50) MAPTKDM4EALDH1A1ALOX15LMNA
SCHEMBL17375980 0.72 HRH3 (0.49) MAPTKDM4EALDH1A1BACE1HPGD
SCHEMBL22494221 0.71 RAB9A (0.62) MAPTKDM4EALDH1A1CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116234800-A Copper complexes for the treatment of neurodegenerative disorders ALS治疗发展学会 2023-06-06 CN disclosed
US-20070275956-A1 Novel Heterocyclic Compounds CADILA HEALTHCARE LIMITED (IN) 2007-11-29 US disclosed
US-20070275956-A1 Novel Heterocyclic Compounds CADILA HEALTHCARE LIMITED (IN) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275956-A1 Novel Heterocyclic Compounds CYP46A1, DHCR7, NPC1L1 MAPT 162/4885KDM4E 4107/4885ALDH1A1 1358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.